title: Considerations on discontinuing natalizumab for the treatment of multiple sclerosis.
authors.forename: Joseph R
authors.initials: JR
authors.lastname: Berger
authors.forename: Diego
authors.initials: D
authors.lastname: Centonze
authors.forename: Giancarlo
authors.initials: G
authors.lastname: Comi
authors.forename: Christian
authors.initials: C
authors.lastname: Confavreux
authors.forename: Gary
authors.initials: G
authors.lastname: Cutter
authors.forename: Gavin
authors.initials: G
authors.lastname: Giovannoni
authors.forename: Ralf
authors.initials: R
authors.lastname: Gold
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Hartung
authors.forename: Fred
authors.initials: F
authors.lastname: Lublin
authors.forename: Augusto
authors.initials: A
authors.lastname: Miravalle
authors.forename: Xavier
authors.initials: X
authors.lastname: Montalban
authors.forename: Paul
authors.initials: P
authors.lastname: O'Connor
authors.forename: Tomas
authors.initials: T
authors.lastname: Olsson
authors.forename: Chris H
authors.initials: CH
authors.lastname: Polman
authors.forename: Olaf
authors.initials: O
authors.lastname: Stuve
authors.forename: Jerry S
authors.initials: JS
authors.lastname: Wolinsky
authors.forename: Tjalf
authors.initials: T
authors.lastname: Ziemssen
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*; D000069442:Natalizumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab